![Severity of overactive bladder symptoms and response to dose escalation in a randomized, double‐blind trial of solifenacin (SUNRISE) - Cardozo - 2013 - BJU International - Wiley Online Library Severity of overactive bladder symptoms and response to dose escalation in a randomized, double‐blind trial of solifenacin (SUNRISE) - Cardozo - 2013 - BJU International - Wiley Online Library](https://bjui-journals.onlinelibrary.wiley.com/cms/asset/7d5aa484-f74d-4035-a9ab-dba741f98b3d/bju11654-fig-0001-m.png)
Severity of overactive bladder symptoms and response to dose escalation in a randomized, double‐blind trial of solifenacin (SUNRISE) - Cardozo - 2013 - BJU International - Wiley Online Library
![PDF) A retrospective study on effectiveness of Solifenacin to treat postoperative urge incontinence de novo, complication of TOT treatment of SUI PDF) A retrospective study on effectiveness of Solifenacin to treat postoperative urge incontinence de novo, complication of TOT treatment of SUI](https://i1.rgstatic.net/publication/288247727_A_retrospective_study_on_effectiveness_of_Solifenacin_to_treat_postoperative_urge_incontinence_de_novo_complication_of_TOT_treatment_of_SUI/links/581f35b208aeccc08af3794c/largepreview.png)
PDF) A retrospective study on effectiveness of Solifenacin to treat postoperative urge incontinence de novo, complication of TOT treatment of SUI
![PDF) Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies PDF) Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies](https://i1.rgstatic.net/publication/338202865_Long-term_efficacy_and_safety_of_solifenacin_in_pediatric_patients_aged_6_months_to_18_years_with_neurogenic_detrusor_overactivity_results_from_two_phase_3_prospective_open-label_studies/links/5ef663cea6fdcc4ca4338fdc/largepreview.png)
PDF) Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies
![A Comparison of the Efficacy and Tolerability of Solifenacin Succinate and Extended Release Tolterodine at Treating Overactive Bladder Syndrome: Results of the STAR Trial - European Urology A Comparison of the Efficacy and Tolerability of Solifenacin Succinate and Extended Release Tolterodine at Treating Overactive Bladder Syndrome: Results of the STAR Trial - European Urology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2000731747/2001937922/gr2.jpg)
A Comparison of the Efficacy and Tolerability of Solifenacin Succinate and Extended Release Tolterodine at Treating Overactive Bladder Syndrome: Results of the STAR Trial - European Urology
![Treatment Outcomes in the STAR Study: A Subanalysis of Solifenacin 5 mg and Tolterodine ER 4 mg - European Urology Treatment Outcomes in the STAR Study: A Subanalysis of Solifenacin 5 mg and Tolterodine ER 4 mg - European Urology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2079015768/2071214055/gr1.jpg)
Treatment Outcomes in the STAR Study: A Subanalysis of Solifenacin 5 mg and Tolterodine ER 4 mg - European Urology
![Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies - Journal of Pediatric Urology Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies - Journal of Pediatric Urology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/f3990489-bcf5-46c0-b8e1-ad49bddc7a21/gr2_lrg.jpg)
Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies - Journal of Pediatric Urology
![Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double‐blind, placebo‐controlled, rising‐dose trial - Cardozo - 2008 - BJU International - Wiley Online Library Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double‐blind, placebo‐controlled, rising‐dose trial - Cardozo - 2008 - BJU International - Wiley Online Library](https://bjui-journals.onlinelibrary.wiley.com/cms/asset/0a188427-eff8-486d-8529-ded45f2fe7dd/bju_7939_f6.gif)
Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double‐blind, placebo‐controlled, rising‐dose trial - Cardozo - 2008 - BJU International - Wiley Online Library
![Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo‐ and tolterodine‐controlled phase 2 dose‐finding study - Chapple - 2004 - BJU International - Wiley Online Library Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo‐ and tolterodine‐controlled phase 2 dose‐finding study - Chapple - 2004 - BJU International - Wiley Online Library](https://bjui-journals.onlinelibrary.wiley.com/cms/asset/19880b64-6a09-4129-9e6f-91ab74ead006/bju_4561_f3b.gif)